Literature DB >> 23948229

Reprint of: Epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination.

Xiaofeng Liang1, Shengli Bi2, Weizhong Yang1, Longde Wang3, Gang Cui3, Fuqiang Cui1, Yong Zhang2, Jianhua Liu1, Xiaohong Gong1, Yuansheng Chen1, Fuzhen Wang1, Hui Zheng1, Feng Wang2, Jing Guo1, Zhiyuan Jia2, Jingchen Ma4, Huaqing Wang1, Huiming Luo1, Li Li1, Shuigao Jin1, Stephen C Hadler5, Yu Wang6.   

Abstract

OBJECTIVE: To determine the prevalence of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core anti-body (anti-HBc) in a representative population in China 14 years after introduction of hepatitis B vaccination of infants.
METHODS: National serosurvey, with participants selected by multi-stage random sampling. Demographics and hepatitis B vaccination history collected by questionnaire and review of vaccination records, and serum tested for HBsAg, antibody to anti-HBc and anti-HBs by ELISA.
FINDINGS: The weighted prevalences of HBsAg, anti-HBs and anti-HBc for Chinese population aged 1-59 years were 7.2%, 50.1%, 34.1%, respectively. HBsAg prevalence was greatly diminished among those age <15 years compared to that found in the 1992 national serosurvey, and among children age <5 years was only 1.0% (90% reduction). Reduced HBsAg prevalence was strongly associated with vaccination among all age groups. HBsAg risk in adults was associated with male sex, Western region, and certain ethnic groups and occupations while risk in children included birth at home or smaller hospitals, older age, and certain ethnic groups (Zhuang and other).
CONCLUSIONS: China has already reached the national goal of reducing HBsAg prevalence to less than 1% among children under 5 years and has prevented an estimated 16-20 million HBV carriers through hepatitis B vaccination of infants. Immunization program should be further strengthened to reach those remaining at highest risk.
Copyright © 2009 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis B; Immunization; Serosurvey

Year:  2013        PMID: 23948229     DOI: 10.1016/j.vaccine.2013.08.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  62 in total

1.  Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia.

Authors:  Pan Zhao; Qing Gao; Qiulian He; Jing Tan
Journal:  Int J Hematol       Date:  2017-06-13       Impact factor: 2.490

2.  The response of hepatitis B vaccination on seronegative adults with different vaccination schedules.

Authors:  Jun Yao; Jing Li; Yongdi Chen; Huan Shan; Xue-wei Dai; Lin-na Yang; Zheng-gang Jiang; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Bing Wang; Tian-sheng Xie; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

4.  Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.

Authors:  Yanping Bao; Sarah Larney; Amy Peacock; Samantha Colledge; Jason Grebely; Matthew Hickman; Louisa Degenhardt; Janni Leung
Journal:  Int J Drug Policy       Date:  2019-05-21

5.  Long-term persistence of anti-HBs after hepatitis B vaccination among isolated anti-HBc positive adults in China: 8-years results.

Authors:  Wen Ren; Jing Li; Ruidong Cheng; Zikang Wu; Ying Liu; Yan Qiu; Jun Yao; Jingjing Ren
Journal:  Hum Vaccin Immunother       Date:  2020-09-11       Impact factor: 3.452

6.  The one year effects of three doses of hepatitis B vaccine as a booster in anti-HBs-negative children 11-15 years after primary immunization; China, 2009-2011.

Authors:  Jun Yao; Huan Shan; Yongdi Chen; Zheng-gang Jiang; Xue-wei Dai; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury.

Authors:  Jin Gu; Shen-Jie Tang; Shou-Yong Tan; Qi Wu; Xia Zhang; Cun-Xu Liu; Xu-Sheng Gao; Bao-Dong Yuan; Li-Jun Han; Ai-Ping Gao; Mei-Ying Wu; Li-Hua Huang; Jun Ma; He-Ping Xiao
Journal:  Int J Clin Exp Med       Date:  2015-03-15

8.  Seroepidemiology of hepatitis B virus infection and impact of vaccination.

Authors:  Peng Huang; Li-Guo Zhu; Ye-Fei Zhu; Ming Yue; Jing Su; Feng-Cai Zhu; Hai-Tao Yang; Yun Zhang; Hong-Bing Shen; Rong-Bin Yu; Xiang-Jun Zhai; Zhi-Hang Peng
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

9.  Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

Authors:  A Blythe Ryerson; Christie R Eheman; Sean F Altekruse; John W Ward; Ahmedin Jemal; Recinda L Sherman; S Jane Henley; Deborah Holtzman; Andrew Lake; Anne-Michelle Noone; Robert N Anderson; Jiemin Ma; Kathleen N Ly; Kathleen A Cronin; Lynne Penberthy; Betsy A Kohler
Journal:  Cancer       Date:  2016-03-09       Impact factor: 6.860

10.  In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.

Authors:  L-L Fu; J Liu; Y Chen; F-T Wang; X Wen; H-Q Liu; M-Y Wang; L Ouyang; J Huang; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2014-06-26       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.